Iranian Scientists Produce Kit to Diagnose Rupture of Fetal Membrane
‘Aminotest’ which was unveiled in the presence of Rouhollah Dehqani, the Iranian Vice-President for Science, Technology and Knowledge-Based Economy,and Seyed Reza Mortazavi, the Governor of Isfahan, is a widely-used and non-invasive test for the pregnant women who have signs of rupture of the amniotic sac.
This test enables accurate, timely and simple diagnosis and helps doctors in quickly diagnosing problems and preventing future problems.
The test kit produced by Yakhteh Fanavar Company is superior in terms of price and accuracy compared to similar samples and has a test accuracy of 98%.
The knowledge-based company enjoys the capacity of producing one million kits per year and can supply 30% of domestic needs.
Earlier, in May, experts at an Iranian company operating in the field of genetic and cellular engineering had also managed to produce a broad range of diagnostics and extraction kits and have offered them to laboratories across the country.
Fazel Gorjipour, the managing director of a knowledge-based company, pointed to the specialized activity in the field of genetics and the production of recombinant proteins and antibodies with research, diagnostic and therapeutic applications in their company, and added, “Considering the interdisciplinary nature of biotechnologies, our activities are related to various fields such as biomaterials, nanomaterials, cell therapies, smart drug delivery and biosensors.”
“At the beginning, the experts at this company focused their production activities on the production of kits for measuring cytokines and biomarkers based on ELISA, and continued to offer to the market products such as the cell death detection kit using the flow cytometry method,” he added.
“During the Covid-19 pandemic, our company was one of the first groups that produced spike antigens of the coronavirus in a recombinant form in mammalian cell hosts. These antigens are the active ingredient of recombinant vaccines and also its RBD part is used as antigen of antibody assay kits to check vaccine immunogenicity,” the manager of the company said.
Gorjipour pointed to the production and supply of cellular and biological products, saying, “Currently, various types of biochemical solutions, cell culture, molecular kits, extraction of nucleic acids, antibodies, recombinant proteins and immunoassay-based kits are being done and produced in this company. Also, the interferon gamma release assay kit for detecting infection with the agent of tuberculosis (Mycobacterium tuberculosis), also known as IGRA, is in the research and development phase in the company.”
“This kit is of particular importance due to the importance of rapid differential diagnosis in the population exposed to tuberculosis given the crisis of population movements in the surrounding countries and especially the eastern neighbors, which are among the areas with a high prevalence of tuberculosis. It controls the spread of this contagious respiratory disease,” he further said.
4155/v
